Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.

Fiche publication

Date publication

avril 2020

Journal

Liver international : official journal of the International Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe

Tous les auteurs :
Kudo M, Galle PR, Llovet JM, Finn RS, Vogel A, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomášek J, Borg C, Dadduzio V, Morimoto M, Pracht M, Jen MH, Ubreva ND, Widau RC, Shinozaki K, Yoshikawa R, Zhu AX

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32279446

Résumé

Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha-fetoprotein (AFP) ≥400 ng/mL showed an overall survival (OS) benefit for ramucirumab. These post-hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP ≥400 ng/mL by three prespecified age subgroups (<65, ≥65 to <75, ≥75 years).